A Double-blind Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness
|ClinicalTrials.gov Identifier: NCT01198106|
Recruitment Status : Unknown
Verified September 2010 by Medical Corps, Israel Defense Force.
Recruitment status was: Recruiting
First Posted : September 9, 2010
Last Update Posted : September 9, 2010
BACKGROUND:flight simulator have become an important component in pilot training. However, they are known to be associated with motion sickness like symptoms defined as Simulator Sickness (SS). Prevention countermeasures against motion sickness have been studied extensively focusing on cholinergic blockers and antihistamines. Most comparataive studies emphasized the effectiveness of scopolamine over outher agents. Evidence, though, on prophylaxis against SS is sparse.
OBJECTIVE: to assess the effectiveness of oral scopolamine versus oral cinnarizine or placebo for SS prevention in helicopter pilots.
DESIGN: a prospective, placebo controlled double-blind.
SETTING: Israel Air Forse (IAF) Helicopter Aircaft vWeapon System Trainer.
PARTICIPANTS: IAF experienced helicopter pilots.
INTERVENTION: 0.6 mg oral scopolamine or 50 mg oral cinnarizine or placebo 1 hour before beginning of a 3 sortie simulator training
|Condition or disease||Intervention/treatment||Phase|
|Simulator Sickness||Drug: scopolamine Drug: cinnarizine||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||A Double-blind Randomized Placebo Controlled Comparison of Scopolamine With Cinnarizin for Prevention of Simulator Sickness|
|Study Start Date :||September 2009|
|Estimated Primary Completion Date :||September 2010|
|Estimated Study Completion Date :||September 2010|
- Drug: scopolamine
0.6 mgOther Name: kwells
- Drug: cinnarizine
50 mgOther Name: stonoron
- Finding more effective treatment to the motion sickness symptoms during and after simulator training. [ Time Frame: 1 year ]To record a significant difference in motion sickness symptoms reduction during and after simulator training, after taking cinnarizine, scopolamine or placebo. We predict that scopolamine will prove to be more effective than cinnarizine with fewer side effects that can compromise pilot's performance during training.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01198106
|Contact: Amit Assa, Dr.||03-7379142|
|base 30 IAF||Recruiting|